Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $158.1 million.

  • Iovance Biotherapeutics' Cash & Equivalents fell 368.61% to $158.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.1 million, marking a year-over-year decrease of 368.61%. This contributed to the annual value of $115.7 million for FY2024, which is 70.16% up from last year.
  • Iovance Biotherapeutics' Cash & Equivalents amounted to $158.1 million in Q3 2025, which was down 368.61% from $132.5 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Cash & Equivalents high stood at $543.5 million for Q1 2023, and its period low was $114.9 million during Q4 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Cash & Equivalents value was $164.2 million (recorded in 2024), while the average stood at $205.6 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Cash & Equivalents plummeted by 7530.97% in 2024 and then soared by 2795.48% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Cash & Equivalents stood at $114.9 million in 2023, then rose by 0.7% to $115.7 million in 2024, then surged by 36.68% to $158.1 million in 2025.
  • Its Cash & Equivalents stands at $158.1 million for Q3 2025, versus $132.5 million for Q2 2025 and $171.7 million for Q1 2025.